Karyopharm reported Phase III Sentry results for selinexor (Xpovio) combined with ruxolitinib in first‑line myelofibrosis: the study met the spleen‑volume reduction co‑primary endpoint but missed the symptom‑score co‑primary. The company highlighted a potentially intriguing overall‑survival signal and plans to meet the FDA to discuss a possible supplemental NDA. Analysts described the data as mixed but noted the spleen and survival signals could frame a regulatory case if safety and efficacy can be contextualized. Karyopharm said it will pursue regulatory dialogue while continuing subgroup and durability analyses.